Mahfouz El Shahawy

Mahfouz El Shahawy

UNVERIFIED PROFILE

Are you Mahfouz El Shahawy?   Register this Author

Register author
Mahfouz El Shahawy

Mahfouz El Shahawy

Publications by authors named "Mahfouz El Shahawy"

Are you Mahfouz El Shahawy?   Register this Author

3Publications

74Reads

22Profile Views

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

N Engl J Med 2015 Apr 15;372(16):1489-99. Epub 2015 Mar 15.

From the University of Iowa, Iowa City (J.G.R.); Point Médical, Dijon (M.F.), Centre Hospitalier Universitaire de Nantes-Hôpital Nord Laennec, Saint-Herblain (M.K.), University Hospital of Lille, Lille (G. Luc), and Sanofi, Chilly-Mazarin (C.L.) - all in France; Clinique des Maladies Lipidiques de Québec, Quebec, QC, Canada (J.B.); Università di Palermo-Policlinico P. Giaccone, Palermo, Italy (M.A.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.S., J.J.P.K.); Lipid Clinic, Oslo University Hospital, Oslo (G. Langslet); University of the Witwatersrand, Johannesburg (F.J.R.); Cardiovascular Center of Sarasota, Sarasota (M.E.S.), and Jacksonville Center for Clinical Research, Jacksonville (M.J.K.) - both in Florida; Westside Medical Associates of Los Angeles, Beverly Hills, CA (N.E.L.); Regeneron Pharmaceuticals, Tarrytown, NY (R.P.); and Sanofi, Bridgewater, NJ (U.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1501031DOI Listing
April 2015